When will the DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER patents expire, and when will generic DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	018268-011	Jan 18, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

This analysis examines the market dynamics and financial trajectory for the pharmaceutical product Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in a plastic container, a commonly used intravenous fluid. The product serves as a source of hydration and electrolytes, vital for patient care across various medical settings.

What is the Current Market Landscape for Dextrose 5%, Sodium Chloride 0.33%, Potassium Chloride 0.075% in Plastic Container?

The market for Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in plastic container is characterized by stable demand driven by its essential role in healthcare. This intravenous solution, often referred to by its constituent ingredients or as a specific type of intravenous fluid, is a staple in hospitals, clinics, and long-term care facilities. Its primary applications include fluid and electrolyte replacement, nutritional support in specific contexts, and as a diluent for other injectable medications.

The global market size for intravenous solutions, which encompasses this specific product, is significant and projected for continued growth. In 2022, the global intravenous fluid market was valued at approximately USD 13.5 billion and is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030, reaching an estimated USD 21.1 billion by 2030 [1]. While this overall figure includes a wide array of intravenous solutions, products like Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% constitute a substantial portion due to their widespread use.

Geographically, North America and Europe represent major markets, driven by well-established healthcare infrastructures and high patient volumes. The Asia-Pacific region is experiencing rapid growth due to increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding medical tourism [1].

The competitive landscape is fragmented, featuring numerous global and regional manufacturers. Key players include B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Otsuka Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. [1]. Competition is often based on product quality, pricing, distribution networks, and manufacturing capacity.

Key Market Drivers:

Increasing Prevalence of Chronic Diseases: Conditions such as diabetes, cardiovascular diseases, and kidney disorders often require fluid and electrolyte management, boosting demand for IV solutions [1].
Growing Geriatric Population: The aging global population leads to an increased need for healthcare services, including intravenous therapies for various age-related conditions.
Advancements in Healthcare Infrastructure: Expanding healthcare facilities and improving access to medical care in developing economies contribute to market growth.
Demand for Ready-to-Use Solutions: Pre-mixed intravenous solutions reduce preparation time and minimize the risk of errors in clinical settings, favoring products like the one in question.

Market Restraints:

Stringent Regulatory Requirements: The manufacturing and approval processes for pharmaceutical products are subject to rigorous quality and safety standards, which can impact production costs and timelines.
Availability of Alternative Therapies: In some cases, oral rehydration or other therapeutic modalities might be considered, although IV administration remains critical for many patients.
Price Sensitivity: Healthcare systems and payers often exert pressure on pricing, influencing profit margins for manufacturers.

What are the Regulatory and Intellectual Property Considerations?

The regulatory pathway for Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in plastic container is primarily governed by agencies such as the U.S. Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe. As a generic intravenous fluid, its approval process typically involves demonstrating bioequivalence to an already approved reference listed drug.

Key Regulatory Aspects:

Abbreviated New Drug Application (ANDA): For generic products in the U.S., an ANDA is filed with the FDA, requiring manufacturers to prove that their product is therapeutically equivalent to a branded counterpart. This includes demonstrating identical active ingredients, dosage form, strength, route of administration, and comparable safety and efficacy [2].
Quality Standards: Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality, purity, and consistency. This involves strict controls over raw materials, manufacturing processes, and finished product testing.
Labeling Requirements: Product labels must comply with regulatory guidelines, including clear identification of active ingredients, excipients, indications, dosage, administration instructions, warnings, and contraindications.
Container Integrity: The plastic container itself is subject to material specifications and testing to ensure it does not leach harmful substances into the solution and maintains sterility.

Intellectual Property (IP):

For a well-established generic product like Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in a plastic container, the primary intellectual property considerations revolve around manufacturing processes and formulation improvements, rather than composition of matter patents on the active ingredients themselves, which are long expired.

Process Patents: Manufacturers may hold patents related to specific manufacturing methods for producing sterile intravenous solutions, improving efficiency, reducing costs, or enhancing product stability.
Formulation Patents: While the basic formulation is generic, novel combinations of excipients or specific stabilization techniques could be patentable if they offer a demonstrable advantage.
Container Technology Patents: Innovations in plastic container design, material science, or sterilization methods for IV bags can also be protected by patents.

As of the current date, there are no active composition of matter patents on the combination of dextrose, sodium chloride, and potassium chloride for this standard intravenous fluid, given its long history of use. Patent activity would likely be focused on optimizing production or delivery systems.

What is the Financial Trajectory and Profitability Outlook?

The financial trajectory for Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in plastic container is largely driven by volume and cost efficiencies. As a widely used generic product, pricing is competitive, and profit margins are typically modest compared to novel patented pharmaceuticals.

Revenue Generation:

Revenue is primarily generated through large-volume sales to hospitals, healthcare systems, and medical distributors. The consistency of demand ensures a stable revenue stream. The market size for intravenous solutions, as previously noted, indicates a substantial revenue pool. The specific contribution of this particular formulation to the overall IV fluid market is difficult to isolate without proprietary sales data from manufacturers, but it is a significant component.

Cost Structure:

The primary cost drivers for manufacturers include:

Raw Materials: Costs of dextrose, sodium chloride, potassium chloride, and purified water.
Packaging: Expense of plastic containers, stoppers, and secondary packaging.
Manufacturing: Overhead associated with sterile manufacturing facilities, energy, and labor.
Quality Control and Regulatory Compliance: Costs associated with testing, validation, and maintaining cGMP standards.
Distribution and Logistics: Warehousing, transportation, and supply chain management.

Profitability Outlook:

Profitability is sensitive to several factors:

Economies of Scale: Larger manufacturers with higher production volumes generally achieve lower per-unit costs, leading to better margins.
Pricing Pressures: Intense competition among generic manufacturers and the negotiating power of large healthcare buyers limit pricing flexibility.
Raw Material Price Fluctuations: Volatility in the costs of chemical components can impact profitability if not effectively hedged.
Operational Efficiency: Streamlined manufacturing processes and supply chain optimization are critical for maintaining profitability.

While individual product margins may be narrow, companies that produce this IV solution as part of a broader portfolio of essential medicines can achieve robust overall financial performance. The financial success hinges on efficient production, strong distribution channels, and securing large-volume contracts.

Projected Financial Trends:

The market is expected to see steady but moderate revenue growth, aligned with the overall IV fluid market CAGR of 5.8% [1]. Companies focusing on cost leadership and supply chain resilience will be best positioned. Innovations in packaging or more efficient manufacturing processes could provide a competitive edge and potentially improve margins, but significant disruptive financial growth is unlikely for this established generic.

What are the Key Challenges and Opportunities?

Key Challenges:

Intense Price Competition: The generic nature of the product leads to a highly competitive pricing environment, squeezing profit margins for manufacturers.
Supply Chain Disruptions: Reliance on global supply chains for raw materials and manufacturing components can make the product vulnerable to disruptions caused by geopolitical events, natural disasters, or pandemics. This has been a significant concern for critical healthcare supplies.
Sterility Assurance: Maintaining absolute sterility throughout the manufacturing process and product shelf-life is paramount and requires significant investment in quality control and specialized facilities. Any breach can lead to product recalls and severe reputational damage.
Regulatory Compliance Burden: Adhering to evolving cGMP standards and other regulatory requirements necessitates ongoing investment in quality systems and validation.

Key Opportunities:

Expanding Emerging Markets: The growing healthcare infrastructure and increasing demand for essential medicines in emerging economies present significant growth opportunities. Manufacturers can leverage their production capabilities to tap into these expanding markets.
Technological Advancements in Packaging: Innovations in plastic container materials and designs could lead to improved product stability, enhanced safety features (e.g., tamper-evident seals), or more sustainable packaging options. These could offer a differentiation point.
Vertical Integration and Supply Chain Resilience: Companies that can achieve greater control over their supply chains, from raw material sourcing to distribution, may be able to mitigate risks and improve cost efficiencies.
Strategic Partnerships and Acquisitions: Collaborations with healthcare providers or distributors, or acquisitions of smaller manufacturers, can expand market reach and consolidate market share.
Efficiency Improvements in Manufacturing: Continuous optimization of manufacturing processes to reduce waste, increase throughput, and lower energy consumption can enhance profitability in a price-sensitive market.

Key Takeaways

Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in a plastic container is a foundational intravenous fluid with stable market demand. The global market is substantial, projected to reach USD 21.1 billion by 2030, driven by chronic disease prevalence and an aging population. Regulatory oversight is stringent, focusing on cGMP compliance and bioequivalence for generic approval. Intellectual property is largely confined to manufacturing processes and formulation enhancements, not the core composition. Profitability relies on economies of scale, operational efficiency, and securing high-volume contracts due to intense price competition. Key challenges include price wars and supply chain vulnerabilities, while opportunities lie in emerging markets, packaging innovations, and enhancing supply chain resilience.

Frequently Asked Questions

What are the primary indications for Dextrose 5%, Sodium Chloride 0.33%, Potassium Chloride 0.075% in plastic container? This solution is indicated for fluid and electrolyte replenishment, providing a source of calories (from dextrose) for patients requiring nutritional support, and serving as a vehicle for administering other compatible intravenous drugs. It is used in situations of dehydration, electrolyte imbalance, and when oral intake is not feasible.
How does the plastic container material impact the product's stability and safety? The plastic container must be inert and not interact with the solution. Materials like polyvinyl chloride (PVC) or non-PVC alternatives are tested for leachables and extractables to ensure patient safety. The container must also maintain the sterility of the solution throughout its shelf life and withstand transport and storage conditions.
What is the typical shelf life for this intravenous solution? The typical shelf life for Dextrose 5%, Sodium Chloride 0.33%, and Potassium Chloride 0.075% in a plastic container is generally 24 months when stored under specified conditions (e.g., room temperature, protected from light). This can vary slightly depending on the specific manufacturer and container type.
Are there significant differences in quality between products from different manufacturers? While all products must meet stringent regulatory standards (e.g., USP monograph in the U.S.), minor variations in manufacturing processes, raw material sourcing, or container technology may exist. However, for approved generic products, the therapeutic equivalence is established, meaning they are expected to have the same clinical effect and safety profile.
What is the potential impact of raw material price volatility on the profitability of this product? Significant fluctuations in the prices of dextrose, sodium chloride, or potassium chloride can directly impact the cost of goods sold for manufacturers. Companies with strong sourcing strategies, long-term supply contracts, or the ability to pass on increased costs through pricing adjustments (though limited in this market) are better positioned to mitigate this risk.

Citations

[1] Grand View Research. (2023). Intravenous Fluid Market Size, Share & Trends Analysis Report By Type (Crystalloids, Colloids), By Application (Hydration, Nutrition, Drug Delivery), By End-use (Hospitals, Clinics, Homecare), By Region, And Segment Forecasts, 2023 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/intravenous-fluid-market

[2] U.S. Food and Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER at DailyMed

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Dextrose 5%, Sodium Chloride 0.33% And Potassium Chloride 0.075% In Plastic Container, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

US Patents and Regulatory Information for DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

Dextrose 5%, Sodium Chloride 0.33%, Potassium Chloride 0.075% in Plastic Container: Market Dynamics and Financial Trajectory